Infectious Diseases Clinical Trial 20193183

[LCID Study Number: 20193183]

A Randomized Double-blind Placebo-controlled Multicenter Phase 3 Study of Efficacy and Safety of AR-301 as Adjunct Therapy to Antibiotics in the Treatment of Ventilator-Associated Pneumonia (VAP) Caused by S. Aureus

The purpose of this study is to evaluate AR-301 (tosatoxumab) as an adjunctive treatment of ventilator-associated pneumonia (VAP) due to Staphylococcus aureus (S. aureus) in combination with standard of care (SOC) antibiotic therapy in patients with confirmed S. aureus infection.

Disease/Condition: Infectious Diseases

Department: Surgical Critical Care

Location(s): Lahey Hospital & Medical Center (Burlington)

Primary Contact Email:

Clinical Trial Details

View NCT ID 03816956 on

Protocol #: 20193183

Principal Investigator(s): Eric Benoit

Study Coordinator(s): Syed Basit Haider

Trial Phase: Sponsor Initiated Study Phase 3